100th つないで、進む FRONTIERS IN LIFE SCIENCE

検索の使い方

Lung Squamous Cell Carcinoma, 75 Cases, Tumor And Matched NAT*. Tissue Arrays|ヒト組織アレイ

掲載日情報：2015/08/07 現在Webページ番号：173287

ティッシューアレイドットコム /
TissueArray.Com LLC
[メーカー略称：USB]

US Biomax社は、豊富なラインナップの組織アレイ、組織切片(凍結、FFPE)を提供しているメーカーです。
US Biomax社のヒト組織アレイ(Lung Squamous Cell Carcinoma, 75 Cases, Tumor And Matched NAT*. Tissue Arrays)をご紹介します。

※ヒト組織アレイは、ドナーからインフォームドコンセントを取得した組織を使用しています。
※ドナーの組織は、HIV、Hepatitis B、Hepatitis Cが陰性であることを確認しています。
※本製品は研究用です。研究用以外には使用できません。

カートに商品を
追加しました。

ヒト組織アレイの価格

[在庫・価格 ：2024年06月06日 00時01分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
詳細 商品名
  • 商品コード
  • メーカー
  • 包装
  • 価格
  • 在庫
  • 法規制等
 納期 文献数
Lung squamous cell carcinoma tissue array, 75 cases, tumor and matched NAT*.
  • お問い合わせ
 2～3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 0
  • お問い合わせ
説明文
法規制等
保存条件 法規備考
掲載カタログ

製品記事 TissueArray.Com社 組織アレイ(Tissue array) 選択ガイド
関連記事 TissueArray.Com社 パラフィン組織スライド／組織アレイの仕様変更につきまして

[在庫・価格 ：2024年06月06日 00時01分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。

Lung squamous cell carcinoma tissue array, 75 cases, tumor and matched NAT*.

文献数： 0

  • お問い合わせ

説明文
法規制等
保存条件 法規備考
掲載カタログ

製品記事 TissueArray.Com社 組織アレイ(Tissue array) 選択ガイド
関連記事 TissueArray.Com社 パラフィン組織スライド／組織アレイの仕様変更につきまして
  • お問い合わせ

目次に戻る

カートに商品を
追加しました。

ヒト組織アレイの特長

Description: Tumor (1 core/case) and NAT (1 core/case). Clinical stage Ⅰ, Ⅱ, Ⅲ, Ⅳ. 100% cases have TNM detail information.
Cores: 150
組織アレイ
Cases: 75
Layout: 16 cols × 10 rows
Core Diameter: 1.5 mm
Thickness: 4 µm
Applications:

Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes: Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.

*Tissue Microarray Slide Types:

  • Unstained: unstained paraffin tissue microarray slide.
  • Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
  • H and E: Hematoxylin and Eosin stained tissue array slide.

目次に戻る

カートに商品を
追加しました。

ヒト組織アレイの仕様表

Pos No. Sex Age Organ Pathology diagnosis Grade Stage TNM Type †
A1 1 M 69 Lung Squamous cell carcinoma G2 IA T1aN0M0 Tumor
A2 2 M 69 Lung NAT NAT
A3 3 M 71 Lung Squamous cell carcinoma G2 IA T1aN0M0 Tumor
A4 4 M 71 Lung NAT NAT
A5 5 M 74 Lung Squamous cell carcinoma G2 IA T1aN0M0 Tumor
A6 6 M 74 Lung NAT NAT
A7 7 M 67 Lung Squamous cell carcinoma G2-G3 IA T1bN0M0 Tumor
A8 8 M 67 Lung NAT NAT
A9 9 F 54 Lung Squamous cell carcinoma G2 IA T1bN0M0 Tumor
A10 10 F 54 Lung NAT NAT
A11 11 M 55 Lung Squamous cell carcinoma G3 IA T1bN0M0 Tumor
A12 12 M 55 Lung NAT NAT
A13 13 M 64 Lung Squamous cell carcinoma G2 IA T1bN0M0 Tumor
A14 14 M 64 Lung NAT NAT
A15 15 M 57 Lung Squamous cell carcinoma G2 IA T1bN0M0 Tumor
A16 16 M 57 Lung NAT NAT
B1 17 M 49 Lung Squamous cell carcinoma G3 IA T1bN0M0 Tumor
B2 18 M 49 Lung NAT NAT
B3 19 M 42 Lung Squamous cell carcinoma G2 IB T2aN0M0 Tumor
B4 20 M 42 Lung NAT NAT
B5 21 M 54 Lung Squamous cell carcinoma G3 IB T2aN0M0 Tumor
B6 22 M 54 Lung NAT NAT
B7 23 M 53 Lung Squamous cell carcinoma G2 IB T2aN0M0 Tumor
B8 24 M 53 Lung NAT NAT
B9 25 M 64 Lung Squamous cell carcinoma G2 IB T2aN0M0 Tumor
B10 26 M 64 Lung NAT NAT
B11 27 M 59 Lung Squamous cell carcinoma G2 IB T2aN0M0 Tumor
B12 28 M 59 Lung NAT NAT
B13 29 M 66 Lung Squamous cell carcinoma G2-G3 IB T2aN0M0 Tumor
B14 30 M 66 Lung NAT NAT
B15 31 M 81 Lung Squamous cell carcinoma G2 IB T2aN0M0 Tumor
B16 32 M 81 Lung NAT NAT
C1 33 M 69 Lung Squamous cell carcinoma G3 IB T2aN0M0 Tumor
C2 34 M 69 Lung NAT NAT
C3 35 M 65 Lung Basal cell carcinoma G3 IB T2aN0M0 Tumor
C4 36 M 65 Lung NAT NAT
C5 37 M 72 Lung Squamous cell carcinoma G2 IB T2aN0M0 Tumor
C6 38 M 72 Lung NAT NAT
C7 39 M 80 Lung Squamous cell carcinoma G1 IB T2aN0M0 Tumor
C8 40 M 80 Lung NAT NAT
C9 41 M 55 Lung Squamous cell carcinoma G2 IB T2aN0M0 Tumor
C10 42 M 55 Lung NAT NAT
C11 43 M 52 Lung Squamous cell carcinoma G2 IB T2aN0M0 Tumor
C12 44 M 52 Lung NAT NAT
C13 45 M 60 Lung Squamous cell carcinoma G2 IB T2aN0M0 Tumor
C14 46 M 60 Lung NAT NAT
C15 47 M 59 Lung Squamous cell carcinoma G2 IIA T2bN0M0 Tumor
C16 48 M 59 Lung NAT NAT
D1 49 M 73 Lung Squamous cell carcinoma G2 IIA T2bN0M0 Tumor
D2 50 M 73 Lung NAT NAT
D3 51 M 59 Lung Squamous cell carcinoma G2 IIA T2bN0M0 Tumor
D4 52 M 59 Lung NAT NAT
D5 53 M 67 Lung Squamous cell carcinoma G2 IIA T2bN0M0 Tumor
D6 54 M 67 Lung NAT NAT
D7 55 M 65 Lung Squamous cell carcinoma G2 IIA T2bN0M0 Tumor
D8 56 M 65 Lung NAT NAT
D9 57 M 65 Lung Squamous cell carcinoma G2 IIA T2aN1M0 Tumor
D10 58 M 65 Lung NAT NAT
D11 59 M 49 Lung Squamous cell carcinoma G1 IIA T2aN1M0 Tumor
D12 60 M 49 Lung NAT NAT
D13 61 M 54 Lung Squamous cell carcinoma G2 IIA T2aN1M0 Tumor
D14 62 M 54 Lung NAT NAT
D15 63 M 56 Lung Squamous cell carcinoma G3 IIA T2aN1M0 Tumor
D16 64 M 56 Lung NAT NAT
E1 65 M 56 Lung Squamous cell carcinoma G2 IIA T2aN1M0 Tumor
E2 66 M 56 Lung NAT NAT
E3 67 M 43 Lung Squamous cell carcinoma G2 IIA T2aN1M0 Tumor
E4 68 M 43 Lung NAT NAT
E5 69 M 59 Lung Squamous cell carcinoma G2 IIA T2aN1M0 Tumor
E6 70 M 59 Lung NAT NAT
E7 71 F 65 Lung Squamous cell carcinoma G2 IIA T2aN1M0 Tumor
E8 72 F 65 Lung NAT NAT
E9 73 M 67 Lung Squamous cell carcinoma G2 IIB T3N0M0 Tumor
E10 74 M 67 Lung NAT NAT
E11 75 M 70 Lung Squamous cell carcinoma G2 IIB T3N0M0 Tumor
E12 76 M 70 Lung NAT NAT
E13 77 M 67 Lung Squamous cell carcinoma G2 IIB T3N0M0 Tumor
E14 78 M 67 Lung NAT NAT
E15 79 M 68 Lung Squamous cell carcinoma G2 IIB T3N0M0 Tumor
E16 80 M 68 Lung NAT NAT
F1 81 M 53 Lung Squamous cell carcinoma G2-G3 IIB T3N0M0 Tumor
F2 82 M 53 NA NAT NAT
F3 83 M 57 Lung Squamous cell carcinoma G2 IIB T3N0M0 Tumor
F4 84 M 57 Lung NAT NAT
F5 85 M 59 Lung Squamous cell carcinoma G2 IIB T2bN1M0 Tumor
F6 86 M 59 Lung NAT NAT
F7 87 M 74 Lung Squamous cell carcinoma G3 IIB T2bN1M0 Tumor
F8 88 M 74 Lung NAT NAT
F9 89 M 59 Lung Squamous cell carcinoma G2 IIB T2bN1M0 Tumor
F10 90 M 59 Lung NAT NAT
F11 91 M 68 Lung Squamous cell carcinoma G1-G2 IIB T2bN1M0 Tumor
F12 92 M 68 Lung NAT NAT
F13 93 M 63 Lung Squamous cell carcinoma G2 IIIA T4N0M0 Tumor
F14 94 M 63 NA NAT NAT
F15 95 M 68 Lung Squamous cell carcinoma G3 IIIA T3N1M0 Tumor
F16 96 M 68 Lung NAT NAT
G1 97 M 72 Lung Squamous cell carcinoma G2-G3 IIIA T3N1M0 Tumor
G2 98 M 72 Lung NAT NAT
G3 99 M 63 Lung Squamous cell carcinoma G3 IIIA T3N1M0 Tumor
G4 100 M 63 Lung NAT NAT
G5 101 M 58 Lung Squamous cell carcinoma G2 IIIA T3N1M0 Tumor
G6 102 M 58 Lung NAT NAT
G7 103 M 63 Lung Squamous cell carcinoma G2 IIIA T3N1M0 Tumor
G8 104 M 63 Lung NAT NAT
G9 105 M 71 Lung Squamous cell carcinoma G3 IIIA T3N1M0 Tumor
G10 106 M 71 Lung NAT NAT
G11 107 F 74 Lung Squamous cell carcinoma G3 IIIA T3N1M0 Tumor
G12 108 F 74 Lung NAT NAT
G13 109 M 52 Lung Squamous cell carcinoma G2 IIIA T3N1M0 Tumor
G14 110 M 52 Lung NAT NAT
G15 111 M 62 Lung Squamous cell carcinoma G2 IIIA T3N1M0 Tumor
G16 112 M 62 Lung NAT NAT
H1 113 M 52 Lung Squamous cell carcinoma G2 IIIA T3N1M0 Tumor
H2 114 M 52 Lung NAT NAT
H3 115 M 68 Lung Squamous cell carcinoma G3 IIIA T3N1M0 Tumor
H4 116 M 68 Lung NAT NAT
H5 117 M 51 Lung Squamous cell carcinoma G1-G2 IIIA T3N1M0 Tumor
H6 118 M 51 Lung NAT NAT
H7 119 M 55 Lung Squamous cell carcinoma G2 IIIA T3N1M0 Tumor
H8 120 M 55 Lung NAT NAT
H9 121 M 60 Lung Squamous cell carcinoma G3 IIIA T3N1M0 Tumor
H10 122 M 60 Lung NAT NAT
H11 123 M 62 Lung Squamous cell carcinoma G1-G2 IIIA T3N1M0 Tumor
H12 124 M 62 Lung NAT NAT
H13 125 F 56 Lung Squamous cell carcinoma G2-G3 IIIA T3N1M0 Tumor
H14 126 F 56 Lung NAT NAT
H15 127 M 53 Lung Squamous cell carcinoma G3 IIIA T3N1M0 Tumor
H16 128 M 53 Lung NAT NAT
I1 129 M 72 Lung Squamous cell carcinoma G3 IIIA T3N1M0 Tumor
I2 130 M 72 Lung NAT NAT
I3 131 M 55 Lung Squamous cell carcinoma G2-G3 IIIA T1bN2M0 Tumor
I4 132 M 55 Lung NAT NAT
I5 133 M 63 Lung Squamous cell carcinoma G1-G2 IIIA T2aN2M0 Tumor
I6 134 M 63 Lung NAT NAT
I7 135 M 70 Lung Squamous cell carcinoma G3 IIIA T2aN2M0 Tumor
I8 136 M 70 Lung NAT NAT
I9 137 M 53 Lung Squamous cell carcinoma G2 IIIB T4N2M0 Tumor
I10 138 M 53 Lung NAT NAT
I11 139 M 63 Lung Squamous cell carcinoma G2-G3 IIIB T2aN3M0 Tumor
I12 140 M 63 Lung NAT NAT
I13 141 M 55 Lung Squamous cell carcinoma G2 IV T4N1M1b Tumor
I14 142 M 55 Lung NAT NAT
I15 143 M 53 Lung Squamous cell carcinoma G2 IV T1N0M1a Tumor
I16 144 M 53 Lung NAT NAT
J1 145 M 71 Lung Squamous cell carcinoma G2-G3 IV ？？M1b Tumor
J2 146 M 71 Lung NAT NAT
J3 147 M 65 Lung Squamous cell carcinoma G3 IV ？？M1b Tumor
J4 148 M 65 Lung NAT NAT
J5 149 M 62 Lung Squamous cell carcinoma G2 IV T3N0M1b Tumor
J6 150 M 62 Lung NAT NAT

*For precise diagnosis, refer to pathology description.

目次に戻る

カートに商品を
追加しました。

ヒト組織アレイのFAQ

US BIOMAX社ヒト組織アレイのFAQはこちら。

目次に戻る

カートに商品を
追加しました。

お問い合わせ先

（テクニカルサポート 試薬担当）

reagent@funakoshi.co.jp

製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。